Interview with Christian Schilling, CEO, Boehringer Ingelheim Austria
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Address: ‘Dr.-Boehringer-Gasse 5-11
A-1121 Wien’
,Austria
Tel: (+43 1) 80 105-0
Web: http://www.boehringer-ingelheim.at/
Boehringer Ingelheim – one of the world‘s 20 leading pharmaceutical companies
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
For more information please visit www.boehringer-ingelheim.com
Boehringer Ingelheim in Austria
Boehringer Ingelheim founded its first subsidiary outside Germany in a Viennese pharmacy in 1948. From these modest beginnings, the Austrian company has developed into a modern high technology concern.
Today the company is of great importance as a cancer research centre and one of the three biopharmaceutical research, development and production centres in the international group. As the Regional Center Vienna it is responsible for the pharmaceutical business (human pharmaceuticals and animal health) and for clinical trials in more than 30 countries in Central and Eastern Europe (including Austria).
Over the last years Boehringer Ingelheim has created 530 new jobs in Vienna and invested around 360 million euros in the Vienna site.
Activities of the Boehringer Ingelheim Regional Center Vienna
• Business responsiblity for Boehringer Ingelheim products in more than 30 countries of Central and Eastern Europa – Human Pharmaceuticals and Animal Health
• International Oncology Research Center
• Clinical Research in all therapeutic areas of the Corporation in Central and Eastern Europe (including Austria and Switzerland), Turkey, South Africa and Israel
• Biopharmaceutical research, development and production
Boehringer Ingelheim Regional Center Vienna
The Regional Center Vienna (RCV) is responsible for the human pharmaceuticals (prescription medicines and over-the-counter products) and animal health business in more than 30 Central and Eastern European countries. Moreover the whole clinical research of the region is managed by the RCV. Vienna is the oncology research center and a center of biopharmaceutical research, development and production in the international group of companies. Boehringer Ingelheim is also engaged in basic research, represented by the Research Institute of Molecular Pathology (IMP) in Vienna. Therefore BI is one of the most research focused pharmaceutical companies in Austria. In 2011 the Boehringer Ingelheim Regional Center Vienna earned 736,2 million euros and had about 3,000 employees in Austria and Eastern Europe.
Animal Health
International Research Center of Oncology
Clinical research in all therapeutic areas of the business association – studies in 15 countries of Central and Eastern Europe (including Austria)
Biopharmaceutical development and manufacturing of pharmaceuticals
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative…
Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the rationale behind Austria’s prioritization of rare diseases and its leading role in the field.…
Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out,…
Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive footprint in the life sciences, its positioning as the start-up hub for Central and Eastern…
Peter Wimmer, country manager of Angelini Austria and Germany, discusses the tailored long-term strategy that this exciting Italian pharmaceutical company is implementing to establish a boutique portfolio and the importance…
Christoph Wahl and Gerlad Weirowski of DHL Global Forwarding Austria discuss the significance of the Austrian affiliate being chosen as lead office for CEE and the company’s life sciences and…
Christoph Sauermann, managing director of Mediclass, an innovative healthcare center, discusses how the complexities of the Austrian healthcare system can be solved through primary healthcare centers, such as Mediclass. Furthermore,…
Rudolf Widmann, CEO and founder of AOP Orphan, the first rare disease-specific European company, discusses the overriding goal to ensure rare disease patients are matched with the correct treatments and…
Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human protein products manufacturer in the world, discuss the strategic significance of Austria to the…
Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations.…
David Kasper, CEO of ARCHIMEDlife, an innovative Austrian company focused on novel laboratory diagnostics, discusses the innovative solution of a dried blood sample in daily routine diagnostics and novel assays…
See our Cookie Privacy Policy Here